Drug Details
General Information of the Drug (ID: DR2863) | ||||
---|---|---|---|---|
Name |
Procarbazine
|
|||
Synonyms |
procarbazine; 671-16-9; Procarbazin; Ibenzmethyzin; Natulan; Ibenzmethyzine; Procarbazin [German]; Procarbazina; Procarbazinum; Procarbazinum [INN-Latin]; Procarbazina [INN-Spanish]; N-Isopropyl-4-((2-methylhydrazinyl)methyl)benzamide; 2-(p-Isopropylcarbamoylbenzyl)-1-methylhydrazine; p-(2-Methylhydrazinomethyl)-N-isopropylbenzamide; 1-Methyl-2-(p-(isopropylcarbamoyl)benzyl)hydrazine; 4-((2-Methylhydrazino)methyl)-N-isopropylbenzamide; Benzamide, N-(1-methylethyl)-4-[(2-methylhydrazino)methyl]-; Ro 4-6467; N-4-Isopropylcarbamoylbenzyl-N'-methylhydrazine; N-(1-Methylethyl)-4-((2-methylhydrazino)methyl)benzamide; N-Isopropyl-p-(2-methylhydrazinomethyl)-benzamide; N-Isopropyl-alpha-(2-methylhydrazino)-p-toluamide; N-Isopropyl-4-[(2-methylhydrazino)methyl]benzamide; CB 400-497; MIH; Procarbazine free base; UNII-35S93Y190K; 4-[(2-methylhydrazinyl)methyl]-N-propan-2-ylbenzamide; N-(1-Methylethyl)-4-[(2-methylhydrazino)methyl]benzamide; PCX; Ro 4-6467/1; 671-16-9 (free base); Benzamide, N-(1-methylethyl)-4-((2-methylhydrazino)methyl)-; CHEBI:71417; 35S93Y190K; CB 400-497; Ibenzmethyzine; MIH; p-Toluamide, N-isopropyl-.alpha.-(2-methylhydrazino)-; Procarbazine [INN:BAN]; 4-[(2-methylhydrazin-1-yl)methyl]-N-(propan-2-yl)benzamide; Procarbazine (INN); CCRIS 2389; HSDB 3250; NCGC00016438-01; Ro-4646711; CAS-366-70-1; EINECS 211-582-2; p-(N'-Methylhydrazinomethyl)-N-isopropylbenzamide; BRN 0958270; SR-01000763375; Procarbazine-[d3]; p-Toluamide, N-isopropyl-alpha-(2-methylhydrazino)-; SRI-10847; MBH (Salt/Mix); Matulane (Salt/Mix); Nathulane (Salt/Mix); Natunalar (Salt/Mix); Prestwick0_001112; Prestwick1_001112; Prestwick2_001112; Prestwick3_001112; DSSTox_CID_1189; SCHEMBL4656; CHEMBL1321; DSSTox_RID_75999; NCIOpen2_004074; DSSTox_GSID_21189; BSPBio_001244; BIDD:GT0183; SPBio_003112; BPBio1_001369; GTPL7278; DTXSID4021189; 4-[(2-methylhydrazinyl)methyl]-N-(propan-2-yl)benzamide; HMS2090J09; Pharmakon1600-01502326; RO-4-6467 FREE BASE; BCP12198; Tox21_301738; 0319AC; NSC759626; STL483417; ZINC19166988; AKOS015891211; AC-4547; CCG-213031; DB01168; MCULE-9065058360; NSC-759626; NCGC00016438-02; NCGC00016438-05; NCGC00255280-01; CAS-671-16-9; NCI60_041703; Ro-4-6467/1; SRI-10847-09; SRI-10847-10; SRI-10847_11; SRI-10847_13; DB-082065; RO-4-6467; FT-0737820; C07402; D08423; 671P169; Q418656; N-Isopropyl-.alpha.-(2-methylhydrazino)-p-toluamide; SR-01000763375-3; N-Isopropyl-4-[(2-methylhydrazino)methyl]benzamide #; Benzamide, N-(1-methylethyl)-4-((2-methylhydrazino)methyl)- (9CI)
Click to Show/Hide
|
|||
Molecular Type |
Small molecule
|
|||
Disease | Hodgkin lymphoma [ICD-11: 2B30] | Approved | [1] | |
Structure |
Click to Download Mol2D MOL |
|||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | ||||
Formula |
C12H19N3O
|
|||
PubChem CID | ||||
Canonical SMILES |
CC(C)NC(=O)C1=CC=C(C=C1)CNNC
|
|||
InChI |
1S/C12H19N3O/c1-9(2)15-12(16)11-6-4-10(5-7-11)8-14-13-3/h4-7,9,13-14H,8H2,1-3H3,(H,15,16)
|
|||
InChIKey |
CPTBDICYNRMXFX-UHFFFAOYSA-N
|
|||
CAS Number |
CAS 671-16-9
|
|||
ChEBI ID | ||||
TTD Drug ID | ||||
DrugBank ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
Vinblastine | Catharanthus roseus | Click to Show/Hide the Molecular Data of This NP | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Experimental
Result(s) |
The treatment of advanced and recurrent Hodgkin's disease with chlorambucil, vinblastine, procarbazine and prednisone in combination. |
Target and Pathway | ||||
---|---|---|---|---|
Target(s) | Human Deoxyribonucleic acid (hDNA) | Molecule Info | [3] |